BioMarin Pharmaceutical Inc. agreed to acquire Alesta Therapeutics in a deal valued at $275 million upfront [2].
The acquisition allows BioMarin to expand its pipeline for rare skeletal and genetic diseases. By absorbing Alesta, the company gains access to ALE1, a drug candidate that could become a first-in-class oral therapy for hypophosphatasia [3, 4].
Financial terms for the agreement include an initial payment of $275 million [2]. Depending on the achievement of certain milestones, the total value of the deal could reach as much as $490 million [3].
Market reaction to the announcement was positive. BioMarin shares rose 4.7% in pre-market trading [1].
The move is part of a broader strategy to broaden the company's reach into skeletal diseases [1, 3]. Hypophosphatasia is a rare genetic disorder that affects bone mineralization, and the development of an oral treatment would represent a shift in how the condition is managed.
BioMarin, which trades on the NASDAQ under the symbol BMRN, has focused its research on rare diseases that often lack effective treatment options [1]. The addition of ALE1 provides a new pathway for growth in the rare disease sector [4].
“BioMarin agreed to acquire Alesta Therapeutics in a deal valued at $275 million upfront.”
This acquisition signals BioMarin's intent to dominate the rare skeletal disease market by shifting toward oral delivery methods. Moving from injectable or complex treatments to an oral therapy like ALE1 could significantly increase patient compliance and market share for hypophosphatasia treatments.
